Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Summary

This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with immunosuppressive therapy in liver transplant recipients.

Timeline

Start

2010-05

Primary completion

2013-05

Completion

2013-05

Drugs

Indications